<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429726</url>
  </required_header>
  <id_info>
    <org_study_id>rAd-p53-H2015002</org_study_id>
    <nct_id>NCT02429726</nct_id>
  </id_info>
  <brief_title>Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion</brief_title>
  <official_title>Recombinant Adenoviral Human p53 Gene With or Without Cisplatin in Treatment of Malignant Pleural - a Phase 2, Double Blinded, Randomized, Active Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen SiBiono GeneTech Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen SiBiono GeneTech Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of this study is to investigate of efficacy and safety of recombinant adenoviral&#xD;
      human p53 Gene (rAd-p53) in treatment of malignant pleural effusion, compared to cisplatin.&#xD;
      This is a phase 2, double blinded, randomized, active controlled study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective of this study is to investigate of efficacy and safety of recombinant adenoviral&#xD;
      human p53 Gene (rAd-p53) in treatment of malignant pleural effusion, compared to cisplatin.&#xD;
      Study design: phase 2, double blinded, randomized, active controlled.Ninety patients with&#xD;
      malignant pleural effusion, who meet the study inclusion criteria and none of exclusion&#xD;
      criteria, will be randomized into 3 treatment groups: rAd-p53, cisplatin, and rAd-p53&#xD;
      combined with cisplatin. The study endpoints are objective response rate, Karnofsky score,&#xD;
      effusion-free survival, and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>from starting study treatment to 3 months</time_frame>
    <description>the rate of complete response and partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effusion-free survival</measure>
    <time_frame>from starting study treatment to 2 years</time_frame>
    <description>effusion-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky Performance Status</measure>
    <time_frame>from starting study treatment to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>from starting study treatment to 30 days after the last treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Malignant Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>rAdp53</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 10^12 viral particles of rAdp53 gene are given in 40 ml of saline by intra-cavity infusion at day of 7, 15 and 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rAdp53 plus cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 10^12 viral particles of rAdp53 gene and cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rAdp53</intervention_name>
    <description>Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion</description>
    <arm_group_label>rAdp53</arm_group_label>
    <other_name>recombinant adenoviral p53 human gene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin will be administered by intra chest cavity infusion</description>
    <arm_group_label>cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rAdp53 plus cisplatin</intervention_name>
    <description>Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion</description>
    <arm_group_label>rAdp53 plus cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. histopathologically diagnosed original cancer with malignant pleural effusion;&#xD;
&#xD;
          2. 18 years or older;&#xD;
&#xD;
          3. with normal tests of hemogram, blood coagulation, liver and kidney function; 6.signed&#xD;
             the informed consent form.&#xD;
&#xD;
          4. signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious blood coagulation disorder, bleeding tendency, platelet &lt; 6 * 1000000000/L;&#xD;
&#xD;
          2. have serious heart, lung function abnormalities or severe diabetes patients;&#xD;
&#xD;
          3. active infection;&#xD;
&#xD;
          4. severe atherosclerosis;&#xD;
&#xD;
          5. AIDS patients;&#xD;
&#xD;
          6. serious thrombotic or embolic events within 6 months;&#xD;
&#xD;
          7. renal insufficiency requiring hemodialysis or peritoneal dialysis;&#xD;
&#xD;
          8. pregnant or lactating women;&#xD;
&#xD;
          9. mental disorder or disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shuanyin Yang, MD</last_name>
    <phone>86-18149098803</phone>
    <email>yangshuanying66@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Wang, MD</last_name>
    <phone>86-13923853040</phone>
    <email>wei.wang@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiao Tong University</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>wei wang, MD</last_name>
      <phone>86-13923853040</phone>
      <email>wei.wang@163.com</email>
    </contact>
    <contact_backup>
      <last_name>shuanying yang, MD</last_name>
      <phone>86-18149098803</phone>
      <email>yangshuanying66@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignant pleural effusion, p53 gene therapy, cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

